Literature DB >> 18274934

siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection.

Yong Chen1, Ram I Mahato.   

Abstract

The main objective was to determine whether a pool of small interfering RNAs (siRNAs) targeting different regions of hepatitis B virus surface antigen (HBsAg) efficiently inhibits hepatitis B virus (HBV) infection. siRNAs targeting different regions of HBsAg were transfected into HBV-producing HepG2.2.15 cells and at 72 h post-transfection, the culture medium was collected for ELISA to determine HBsAg, while total RNA was isolated from the cells for real-time PCR. Three siRNA sequences that efficiently inhibited HBV infection were converted into small hairpin RNAs (shRNAs) and then cloned into a single plasmid psiSTRIKE driven by a single U6 promoter. These shRNA expressing plasmids were tested for HBsAg gene silencing in HepG2.2.15 cells. A pool of siRNAs targeting HBsAg efficiently inhibited HBV replication and antigen expression when transfected into HepG2.2.15 cells, compared with the use of single siRNA. Similarly, the plasmid encoding three different shRNAs driven by a single U6 promoter was more effective in silencing HBsAg at DNA, mRNA and protein levels compared with the plasmid encoding single shRNA. No apoptotic change was observed in the cells when the plasmid was transfected at a dose of 0.5-2 microg/1 x 10(6) cells after complex formation with Lipofectamine LTX. Furthermore, transfection with siRNA or shRNA did not increase interferon-gamma (IFNs-gamma) release, suggesting no induction of IFN response. In conclusion, a pool of chemically synthesised siRNAs as well as the shRNA expression plasmid encoding multiple shRNAs targeting different regions of HBsAg showed high gene silencing in HepG2.2.15 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18274934      PMCID: PMC2778861          DOI: 10.1080/10611860701878750

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  38 in total

1.  Antiviral treatment for chronic hepatitis B.

Authors:  C L Lai; P C Wu
Journal:  Hong Kong Med J       Date:  1997-09       Impact factor: 2.227

2.  Breakthrough of the year. Small RNAs make big splash.

Authors:  Jennifer Couzin
Journal:  Science       Date:  2002-12-20       Impact factor: 47.728

3.  Silencing gene expression with Dicer-generated siRNA pools.

Authors:  Jason W Myers; James E Ferrell
Journal:  Methods Mol Biol       Date:  2005

4.  Primary hepatocellular carcinoma.

Authors:  J R Wands; H E Blum
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

5.  RNAi in C. elegans: soaking in the genome sequence.

Authors:  H Tabara; A Grishok; C C Mello
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

6.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 7.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

8.  Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro.

Authors:  Marjorie A Robbins; Mingjie Li; Irene Leung; Haitang Li; Doris V Boyer; Yong Song; Mark A Behlke; John J Rossi
Journal:  Nat Biotechnol       Date:  2006-04-30       Impact factor: 54.908

9.  Durability of serologic response after lamivudine treatment of chronic hepatitis B.

Authors:  Jules L Dienstag; Janusz Cianciara; Selim Karayalcin; Kris V Kowdley; Bernard Willems; Stanilav Plisek; Mary Woessner; Stephen Gardner; Eugene Schiff
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

10.  Studies of HBV replication during acute hepatitis followed by recovery and acute hepatitis progressing to chronic disease.

Authors:  A S Lok; P Karayiannis; T P Jowett; M J Fowler; P Farci; J Monjardino; H C Thomas
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

View more
  8 in total

Review 1.  RNA interference for improving the outcome of islet transplantation.

Authors:  Feng Li; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2010-12-13       Impact factor: 15.470

2.  TGF-beta1 gene silencing for treating liver fibrosis.

Authors:  Kun Cheng; Ningning Yang; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

3.  Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene.

Authors:  Feng Li; Ram I Mahato
Journal:  J Gene Med       Date:  2009-09       Impact factor: 4.565

4.  VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA.

Authors:  Nishant Thakur; Abid Qureshi; Manoj Kumar
Journal:  Nucleic Acids Res       Date:  2011-12-01       Impact factor: 16.971

5.  VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses.

Authors:  Abid Qureshi; Nishant Thakur; Manoj Kumar
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

6.  Significant inhibition of re-emerged and emerging swine enteric coronavirus in vitro using the multiple shRNA expression vector.

Authors:  Kai Li; Hao Li; Zhen Bi; Deping Song; Fanfan Zhang; Dan Lei; Suxian Luo; Zhiquan Li; Wang Gong; Dongyan Huang; Yu Ye; Yuxin Tang
Journal:  Antiviral Res       Date:  2019-03-21       Impact factor: 5.970

Review 7.  A review on current status of antiviral siRNA.

Authors:  Abid Qureshi; Vaqar Gani Tantray; Altaf Rehman Kirmani; Abdul Ghani Ahangar
Journal:  Rev Med Virol       Date:  2018-04-15       Impact factor: 6.989

Review 8.  A Novel Approach of Antiviral Drugs Targeting Viral Genomes.

Authors:  Phuong Thi Hoang; Quynh Xuan Thi Luong; Ramadhani Qurrota Ayun; Yongjun Lee; Thuy Thi Bich Vo; Taehyun Kim; Sukchan Lee
Journal:  Microorganisms       Date:  2022-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.